Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perseus: Daratumumab + VRd vs VRd in Newly Diagnosed Multiple Myeloma
NCT03710603Phase 3Active, not recruiting
- Start
- Dec 2018
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised trial of daratumumab in multiple myeloma (MM) (2 arms). Primary endpoint: Progression Free Survival at 54.41 months. Started Dec 2018; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03710603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03710603.